High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
309.76M
+199.81%
-0.725
-73.25%
319.81M
+133.01%
0.172
-105.17%
372.88M
+75.22%
1.622
-185.35%
Estimates Revision
The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 1.12% over the past three months. During the same period, the stock price has changed by 41.63%.
Revenue Estimates for FY2025
Revise Upward
+1.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.07%
In Past 3 Month
Stock Price
Go Up
+41.63%
In Past 3 Month
16 Analyst Rating
Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 506.43 USD with a low forecast of 266.00 USD and a high forecast of 590.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
1 Hold
1 Sell
Strong Buy
Current: 528.940
Low
266.00
Averages
506.43
High
590.00
Current: 528.940
Low
266.00
Averages
506.43
High
590.00
H.C. Wainwright
Buy
maintain
$500 -> $568
2025-11-11
New
Reason
H.C. Wainwright
Price Target
$500 -> $568
2025-11-11
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Madrigal Pharmaceuticals to $568 from $500 and keeps a Buy rating on the shares. The company presented positive two-year data from the open-label compensated metabolic dysfunction-associated steatohepatitis cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial, the analyst tells investors in a research note. The firm says thestudy bolsters confidence for Rezdiffra's efficacy in compensated cirrhosis patients. It believes Rezdiffra should remain the default oral backbone as the field moves toward combination therapy.
Citizens JMP
Outperform
maintain
$485 -> $527
2025-11-05
Reason
Citizens JMP
Price Target
$485 -> $527
2025-11-05
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Madrigal Pharmaceuticals to $527 from $485 and keeps an Outperform rating on the shares. Rezdiffra sales of $287M beat consensus estimates, driven by robust demand, with more than 29,500 patients now on the therapy in the U.S., the analyst tells investors in a research note. The firm is looking forward to Madrigal's presence and MASH leadership at the Liver Meeting, which is kicking off later this week, where Rezdiffra will be featured in numerous presentations covering efficacy, safety, real-world use, quality of life improvements, early biomarkers, and durability of fibrosis regression.
Clear Street
Buy
maintain
$431 -> $533
2025-11-04
Reason
Clear Street
Price Target
$431 -> $533
2025-11-04
maintain
Buy
Reason
Clear Street raised the firm's price target on Madrigal Pharmaceuticals to $533 from $431 and keeps a Buy rating on the shares to reflect Rezdiffra's continued strong performance, even as Wegovy enters the F2-F3 MASH market. As a result of Rezdiffra's sustained growth, the firm has increased its peak penetration assumption to 20% from 15% for F2-F3 MASH, the analyst noted.
Cantor Fitzgerald
Neutral -> Overweight
upgrade
2025-11-04
Reason
Cantor Fitzgerald
Price Target
2025-11-04
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald upgraded Madrigal Pharmaceuticals to Overweight from Neutral.
Cantor Fitzgerald
Prakhar Agrawal
Neutral -> Overweight
upgrade
2025-11-04
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-11-04
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald analyst Prakhar Agrawal upgraded Madrigal Pharmaceuticals to Overweight from Neutral. The company reported another strong quarter for Rezdiffra, which outperformed high investor expectations, the analyst tells investors in a research note. Cantor says that with better clarity on Madrigal's 2026 growth and "no major near-term headwinds for the stock," it is less concerned about the company's valuation. It believes Madrigal see profitability in 2026.
BofA
Underperform
to
Neutral
upgrade
$266 -> $445
2025-11-03
Reason
BofA
Price Target
$266 -> $445
2025-11-03
upgrade
Underperform
to
Neutral
Reason
BofA upgraded Madrigal Pharmaceuticals to Neutral from Underperform with a price target of $445, up from $266.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL.O) is 141.49, compared to its 5-year average forward P/E of -17.61. For a more detailed relative valuation and DCF analysis to assess Madrigal Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-17.61
Current PE
141.49
Overvalued PE
22.89
Undervalued PE
-58.11
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-10.44
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.46
Undervalued EV/EBITDA
-26.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
52.13
Current PS
528.32
Overvalued PS
159.40
Undervalued PS
-55.13
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 147.47% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.46% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 147.47% over the last month.
Sold
Bought
MDGL News & Events
Events Timeline
(ET)
2025-11-10
08:18:24
Madrigal Pharmaceuticals unveils updated findings on Rezdiffra
2025-11-04 (ET)
2025-11-04
07:05:31
Madrigal Pharmaceuticals announces Q3 EPS of $5.08, up from $4.92 a year ago.
2025-08-20 (ET)
2025-08-20
05:43:00
Citizens JMP Increases Madrigal Pharmaceuticals Price Target to $485 from $483
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/7c9eca16a616349da5e869aa09aac3b14d19e8370c1966bc7c5790f8f90f6f35.jpg)
Preview
2.0
11-12NASDAQ.COMMDGL Surpasses Average Analyst Price Target
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0ed627587b59ba0b3eab09a080a5fbd5d7fedb16ff16fe4c4f20de5dfd33ebd5.png)
Preview
2.0
11-09BenzingaExpedia, Sandisk, and Penumbra Rank Among the Top 10 Large-Cap Winners Last Week (Nov. 3-Nov. 7): Is Your Portfolio Included?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/1e4a50a0eb59ee173144b0f446d1f93774a7054719fd78e5fc043f7e3eb0c521.jpg)
Preview
8.0
11-05NASDAQ.COMSignificant Options Activity on Tuesday: MDGL, HOG, SRPT
Sign Up For More News
People Also Watch
FAQ
What is Madrigal Pharmaceuticals Inc (MDGL) stock price today?
What is Madrigal Pharmaceuticals Inc (MDGL)'s business?
What is the price predicton of MDGL Stock?
What is Madrigal Pharmaceuticals Inc (MDGL)'s revenue for the last quarter?
What is Madrigal Pharmaceuticals Inc (MDGL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Madrigal Pharmaceuticals Inc (MDGL)'s fundamentals?
How many employees does Madrigal Pharmaceuticals Inc (MDGL). have?